Published in Lancet on January 29, 1990
Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis (1994) 1.46
HLA-B27 alters the response to tumor necrosis factor α and promotes osteoclastogenesis in bone marrow monocytes from HLA-B27-transgenic rats. Arthritis Rheum (2013) 1.46
Osteoporosis in inflammatory joint diseases. Osteoporos Int (2010) 1.21
Osteoimmunology and osteoporosis. Arthritis Res Ther (2011) 1.20
Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. Rheumatol Int (2005) 1.19
Ankylosing spondylitis and bone mineral density--what is the ideal tool for measurement? Rheumatol Int (2004) 1.14
Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther (2012) 1.13
Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int (2005) 1.08
Determinants of hyperkyphosis in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 0.99
Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis (1993) 0.99
Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies. Clin Rheumatol (2010) 0.99
High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol (2012) 0.97
The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int (2009) 0.94
Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int (2004) 0.92
Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int (2010) 0.89
Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis (1995) 0.89
High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int (2011) 0.88
Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int (2003) 0.86
Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study. Osteoporos Int (2014) 0.82
Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis. Rheumatol Int (2009) 0.81
Osteoimmunology and bone homeostasis: relevance to spondyloarthritis. Curr Rheumatol Rep (2013) 0.81
Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcif Tissue Int (2017) 0.79
Inflammation, bone loss and fracture risk in spondyloarthritis. RMD Open (2015) 0.79
Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis. Clin Rheumatol (2004) 0.78
Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis. Rheumatol Int (2012) 0.78
Spondylodiscitis and pseudarthrosis in a patient with enteropathic spondyloarthropathy. Ann Rheum Dis (1991) 0.78
Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT): 10-year follow-up. BMC Musculoskelet Disord (2011) 0.77
Anti-Inflammatory Activity of Water-Soluble Polysaccharide of Agaricus blazei Murill on Ovariectomized Osteopenic Rats. Evid Based Complement Alternat Med (2013) 0.77
[Inflammation and bone : Osteoimmunological aspects]. Z Rheumatol (2016) 0.77
Bone mineral density in patients with symptoms suggestive of spondyloarthritis. Osteoporos Int (2015) 0.76
Risk factors for urolithiasis in patients with ankylosing spondylitis: a prospective case-control study. Urolithiasis (2016) 0.75
Analysis on the situation of subjective well-being and its influencing factors in patients with ankylosing spondylitis. Health Qual Life Outcomes (2016) 0.75
Spinal fractures in patients with ankylosing spondylitis. Rheumatol Int (2016) 0.75
Urolithiasis as an extraarticular manifestation of ankylosing spondylitis. Rheumatol Int (2017) 0.75
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol (1994) 11.17
Striking prevalence of ankylosing spondylitis in "healthy" w27 positive males and females. N Engl J Med (1975) 4.25
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum (1997) 4.14
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol (1994) 4.00
Clinical history as a screening test for ankylosing spondylitis. JAMA (1977) 3.60
Calcium-mediated apoptosis in a plant hypersensitive disease resistance response. Curr Biol (1996) 3.58
Sex ratio in the spondyloarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol (1993) 3.39
Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab (1983) 3.27
Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection. Arch Pediatr Adolesc Med (1995) 2.61
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
Bone loss as well as bone formation is a feature of progressive ankylosing spondylitis. Br J Rheumatol (1990) 2.03
Agitated dementia: drug vs nondrug treatment. Cleve Clin J Med (1998) 2.00
1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol (1984) 1.97
Reiter's syndrome. Evaluation of preliminary criteria for definite disease. Arthritis Rheum (1981) 1.97
The hand radiograph as a diagnostic discriminant between seropositive and seronegative 'rheumatoid arthritis': a controlled study. Ann Rheum Dis (1983) 1.96
Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis (2000) 1.92
Childhood growth, physical activity, and peak bone mass in women. J Bone Miner Res (1995) 1.84
Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet (2001) 1.82
Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol (2001) 1.82
The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum (1998) 1.80
HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis (1996) 1.79
Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76
An "experimental" epidemic of Reiter's syndrome revisited. Follow-up evidence on genetic and environmental factors. Ann Intern Med (1976) 1.74
The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol (1996) 1.73
Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest (1997) 1.71
Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol (2001) 1.71
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Treatment of intractable rheumatoid arthritis with total lymphoid irradiation. N Engl J Med (1981) 1.69
The structures of RNase A complexed with 3'-CMP and d(CpA): active site conformation and conserved water molecules. Protein Sci (1994) 1.68
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Effect of prehospital advanced life support on outcomes of major trauma patients. J Trauma (2000) 1.56
The chronicity of symptoms and disability in Reiter's syndrome. An analysis of 131 consecutive patients. Ann Intern Med (1979) 1.53
Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol (1986) 1.53
1 alpha,25-dihydroxyvitamin D3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T lymphocytes, augments production of the monokine, mononuclear cell factor. J Clin Invest (1984) 1.52
A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI) J Rheumatol (1995) 1.49
The impact of new national HIV testing guidelines at a district general hospital in an area of high HIV seroprevalence. J R Coll Physicians Edinb (2011) 1.46
Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet (1993) 1.45
Osteoporosis in treated adult coeliac disease. Gut (1995) 1.43
A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum (1998) 1.41
Genetic control of levels of murine kidney glucuronidase mRNA in response to androgen. Proc Natl Acad Sci U S A (1983) 1.41
The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell (1999) 1.40
Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol (2003) 1.40
The natural history of ankylosing spondylitis: is the disease really changing? J Rheumatol (1989) 1.40
Increasing age at presentation for patients with ankylosing spondylitis. Ann Rheum Dis (1992) 1.39
Atypical antineutrophil cytoplasmic antibodies in patients with ankylosing spondylitis. Br J Rheumatol (1995) 1.38
Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res (1999) 1.37
The acute-phase response after bisphosphonate administration. Calcif Tissue Int (1987) 1.29
The clinical impact of metabolic bone disease in coeliac disease. Postgrad Med J (2001) 1.28
Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol (1999) 1.28
Persistent effects of a message counter-marketing light cigarettes: results of a randomized controlled trial. Addict Behav (2001) 1.28
Low levels of vitamin D in North Indian children with newly diagnosed type 1 diabetes. Pediatr Diabetes (2010) 1.28
Multiple interactions of PRK1 with RhoA. Functional assignment of the Hr1 repeat motif. J Biol Chem (1998) 1.28
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) (1999) 1.28
Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. Arthritis Rheum (1983) 1.25
Dual chamber pacing: how many patients remain in DDD mode over the long term? Br Heart J (1995) 1.25
HLA-B27: to type of not to type? Ann Intern Med (1980) 1.23
Reiter's syndrome following epidemic shigellosis. J Rheumatol (1982) 1.23
Observer variation in grading sacroiliac radiographs in HLA-B27 positive individuals. J Rheumatol (1983) 1.23
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Selective IgA deficiency and spondyloarthropathy: a distinct disease? Ann Rheum Dis (1990) 1.20
Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol (1990) 1.20
Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int (2001) 1.20
Illustrations from the Wellcome Institute Library. The Wellcome collection of papers relating to Edward Jenner. Med Hist (1985) 1.19
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) (2004) 1.17
Ankylosing spondylitis in women and men: a case-control study. J Rheumatol (1983) 1.15
The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis. Arthritis Rheum (1998) 1.14
Search for Reiter's syndrome after an outbreak of Shigella sonnei dysentery. J Rheumatol (1980) 1.13
Physical restraint use in the hospital setting: unresolved issues and directions for research. Milbank Q (1996) 1.13
Bone mineral density and osteoarthritis. Ann Rheum Dis (1992) 1.11
Use of clinical risk factors to identify postmenopausal women with vertebral fractures. Osteoporos Int (2006) 1.11
Do acute care for elders units increase hospital costs? A cost analysis using the hospital perspective. J Am Geriatr Soc (1997) 1.11
Physicians and surgeons in sixteenth-century Venice. Med Hist (1979) 1.11
Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum (2001) 1.10
Safety in laparoscopy. J Reprod Med (1974) 1.09
Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis (2003) 1.08
Effect of a gluten free diet on osteopenia in adults with newly diagnosed coeliac disease. Gut (1996) 1.08
Crystal structure of RNase T1 with 3'-guanylic acid and guanosine. J Biol Chem (1994) 1.07
Non-B27 MHC associations of ankylosing spondylitis. Genes Immun (2006) 1.06
Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol (1995) 1.06
A genetic map of soybean (Glycine max L.) using an intraspecific cross of two cultivars: 'Minosy' and 'Noir 1'. Theor Appl Genet (1993) 1.06
Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet (2000) 1.05
Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys (1997) 1.05
Band 3 mutations, renal tubular acidosis and South-East Asian ovalocytosis in Malaysia and Papua New Guinea: loss of up to 95% band 3 transport in red cells. Biochem J (2000) 1.05
Socioeconomic status in ankylosing spondylitis: relationship between occupation and disease activity. J Rheumatol (1997) 1.04
Isolation and expression in Escherichia coli of a cDNA clone encoding human beta-glucuronidase. Gene (1985) 1.02
The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol (2000) 1.01
Persistent fetal haemoglobin and falsely high glycosylated haemoglobin levels. Br Med J (Clin Res Ed) (1984) 1.01
Objective threshold selection procedure (OTS) for segmentation of scanning laser confocal microscope images. J Microbiol Methods (2001) 1.00
An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores. J Rheumatol (1996) 0.99
The epidemiology of spondylodiscitis in ankylosing spondylitis--a controlled study. Br J Rheumatol (1996) 0.99
Ankylosing spondylitis. Clin Rheum Dis (1985) 0.99
New light on uveitis in ankylosing spondylitis. J Rheumatol (1991) 0.99
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther (2009) 0.99